St. Jude Medical estimates raised by 5% at UBS UBS raised St. Jude estimates by 5% following the company's new $1B repurchase plan. The firm believes the repurchase is 2-3x greater than investors were expecting and is a major vote of confidence by the board. Shares are Buy rated with a $44 price target.
News For STJ From The Last 14 Days
Check below for free stories on STJ the last two weeks.
